GIOTRIF 20MG FILM-COATED TABLETS Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

giotrif 20mg film-coated tablets

boehringer ingelheim (malaysia) sdn. bhd. - afatinib dimaleate -

GIOTRIF 40MG FILM-COATED TABLETS Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

giotrif 40mg film-coated tablets

boehringer ingelheim (malaysia) sdn. bhd. - afatinib dimaleate -

GIOTRIF 30MG FILM-COATED TABLETS Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

giotrif 30mg film-coated tablets

boehringer ingelheim (malaysia) sdn. bhd. - afatinib dimaleate -

GIOTRIF 50MG FILM-COATED TABLETS Malasía - enska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

giotrif 50mg film-coated tablets

boehringer ingelheim (malaysia) sdn. bhd. - afatinib dimaleate -

Afanix 40 mg Tablet Kenía - enska - Pharmacy and Poisons Board

afanix 40 mg tablet

beacon medicare limited 9/b/2, toyenbee circular road, motijheel, - afatinib - tablet - afatinib 40mg - afatinib

GIOTRIF 20 MG Ísrael - enska - Ministry of Health

giotrif 20 mg

boehringer ingelheim israel ltd. - afatinib as dimaleate - film coated tablets - afatinib as dimaleate 20 mg - afatinib - giotrif as monotherapy is indicated for the treatment of: • egfr tki-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutation(s);• locally advanced or metastatic nsclc of squamous histology progressing on or after platinum-based chemotherapy.

GIOTRIF 30 MG Ísrael - enska - Ministry of Health

giotrif 30 mg

boehringer ingelheim israel ltd. - afatinib as dimaleate - film coated tablets - afatinib as dimaleate 30 mg - afatinib - giotrif as monotherapy is indicated for the treatment of: • egfr tki-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutation(s);• locally advanced or metastatic nsclc of squamous histology progressing on or after platinum-based chemotherapy.

GIOTRIF 40 MG Ísrael - enska - Ministry of Health

giotrif 40 mg

boehringer ingelheim israel ltd. - afatinib as dimaleate - film coated tablets - afatinib as dimaleate 40 mg - afatinib - giotrif as monotherapy is indicated for the treatment of: • egfr tki-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutation(s);• locally advanced or metastatic nsclc of squamous histology progressing on or after platinum-based chemotherapy.

GIOTRIF 50 MG Ísrael - enska - Ministry of Health

giotrif 50 mg

boehringer ingelheim israel ltd. - afatinib as dimaleate - film coated tablets - afatinib as dimaleate 50 mg - afatinib - giotrif as monotherapy is indicated for the treatment of: • egfr tki-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutation(s);• locally advanced or metastatic nsclc of squamous histology progressing on or after platinum-based chemotherapy.

Giotrif Evrópusambandið - enska - EMA (European Medicines Agency)

giotrif

boehringer ingelheim international gmbh - afatinib - carcinoma, non-small-cell lung - antineoplastic agents - giotrif as monotherapy is indicated for the treatment ofepidermal growth factor receptor (egfr) tki-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating egfr mutation(s);locally advanced or metastatic nsclc of squamous histology progressing on or after platinum-based chemotherapy.